Robeco Institutional Asset Management B.V. Acquires 86,494 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Robeco Institutional Asset Management B.V. lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 691,607 shares of the medical research company’s stock after purchasing an additional 86,494 shares during the period. Robeco Institutional Asset Management B.V. owned 0.18% of Thermo Fisher Scientific worth $344,144,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $25,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $30,000. Noble Wealth Management PBC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $35,000. Finally, Cassady Schiller Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 89.2% during the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 33 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TMO shares. Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Citigroup decreased their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. UBS Group decreased their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Finally, Robert W. Baird reduced their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $604.05.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $410.45 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The company has a 50 day moving average price of $410.39 and a 200 day moving average price of $485.33. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The stock has a market capitalization of $154.94 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the previous year, the company posted $5.11 EPS. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s payout ratio is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.